EGFR and non-small cell lung carcinoma: In this study, we evaluated the inhibitory activity of two major constituents, asiaticoside and asiatic acid, against both wild-type and double-mutant (L858R/T790M) EGFR, and further examined the anticancer effects of the more potent compound in human NSCLC cell lines expressing wild-type EGFR (A549) and double-mutant EGFR (H1975).